MedTrace Logo

A Study to Evaluate the Safety and Effectiveness of Mirogabalin in Chinese Adult Patients With Diabetic Peripheral Neuropathic Pain (DPNP) in Real-world Clinical Practice Setting (ReMIssion Study)

NCT06812117 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 721

Last updated 2026-03-30

No results posted yet for this study

Summary

This study will evaluate the safety and effectiveness of mirogabalin in adult patients with diabetic peripheral neuropathic pain (DPNP) in real-world clinical practice setting in China.

Conditions

  • Diabetic Peripheral Neuropathic Pain

Interventions

OTHER

No Drug

This is an non-interventional, observational study. No drug will be provided or administered as part of this protocol; however, participants on mirogabalin will be enrolled in this study.

Sponsors & Collaborators

Principal Investigators

  • Project Manager · Daiichi Sankyo Co., Ltd.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-24
Primary Completion
2026-07-24
Completion
2026-07-24

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06812117 on ClinicalTrials.gov